Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01780662 · OUTCOME

Correlation Between Micro Ribonucleic Acid (miRNA) and Disease Response to Protocol Treatment

Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma · Source last updated 2021-10-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
From the end of first dose to the end of last dose (Up to 13 Months)

What was measured

Limit to 41 evaluable patients who received dose 1.8 mg/kg

Analysis population: These samples were banked but not analyzed, due to a change in research priorities.

Groups in this outcome

Treatment (Brentuximab Vedotin, Gemcitabine Hydrochloride)

Patients receive brentuximab vedotin IV over 30 minutes on day 1 and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Treatment repeats every 21 days for up to 15 more courses in the absence of disease progression or unacceptable toxicity. Patients with CR after any course may go off protocol therapy for stem cell transplant. Brentuximab Vedotin: Given IV Gemcitabine Hydrochloride: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Brentuximab Vedotin, Gemcitabine Hydrochloride)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Limit to 41 evaluable patients who received dose 1.8 mg/kg
groups
  1. description
    Patients receive brentuximab vedotin IV over 30 minutes on day 1 and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Treatment repeats every 21 days for up to 15 more courses in the absence of disease progression or unacceptable toxicity. Patients with CR after any course may go off protocol therapy for stem cell transplant. Brentuximab Vedotin: Given IV Gemcitabine Hydrochloride: Given IV
    id
    OG000
    title
    Treatment (Brentuximab Vedotin, Gemcitabine Hydrochloride)
population Description
These samples were banked but not analyzed, due to a change in research priorities.
reporting Status
POSTED
time Frame
From the end of first dose to the end of last dose (Up to 13 Months)
title
Correlation Between Micro Ribonucleic Acid (miRNA) and Disease Response to Protocol Treatment
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice